Physician profile
Molly Orourke
NPI 1497062566
$1,043.73
in general payments reported to CMS, 2019-2025
15 companies · $129 in 2025
The $129 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $67.04 · 2021: $226 · 2022: $113 · 2023: $210 · 2024: $173 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $289.13 | 2019-2024 | Jornay Pm |
| Neurelis, INC. | $200.19 | 2021-2023 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $134.75 | 2019-2025 | Elaprase |
| Supernus Pharmaceuticals, INC. | $68.42 | 2021-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $65.56 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $55.38 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $44.48 | 2022-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $35.86 | 2024-2025 | |
| Daiichi Sankyo INC. | $31.21 | 2019-2021 | |
| Novo Nordisk INC | $31.07 | 2020 | |
| Glaxosmithkline, LLC. | $24.75 | 2019-2021 | |
| Pfizer INC. | $18.99 | 2019 | |
| Phadia US INC. | $18.37 | 2025 | Immunocap |
| Janssen Pharmaceuticals, INC | $14.53 | 2024 | Spravato |
| Gilead Sciences, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Orourke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.